Glaukos Executive Navratil Executes Pre-Arranged Stock Sale Amid Regulatory and Clinical Developments
Glaukos Corporation (NASDAQ: GKOS) Chief Development Officer Tomas Navratil executed a stock sale totaling $99,566 on July 1, 2026, selling 716 shares at $139.06 each under a Rule 10b5-1 trading plan established in March 2026. Following the transaction, Navratil retained direct ownership of 87,634 shares, including 38,817 unvested restricted stock …